412 related articles for article (PubMed ID: 9480608)
1. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D
Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608
[TBL] [Abstract][Full Text] [Related]
2. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
3. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experience with Mercilon and Marvelon with special reference to ovarian function].
Mall-Haefeli M; Werner-Zodrow I; Huber PR
Geburtshilfe Frauenheilkd; 1991 Jan; 51(1):34-8. PubMed ID: 1827418
[TBL] [Abstract][Full Text] [Related]
6. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
7. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman AB; Koontz SL; Nichols MD; Jensen JT
Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938
[TBL] [Abstract][Full Text] [Related]
8. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of two monophase oral contraceptives with desogestrel].
Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
[TBL] [Abstract][Full Text] [Related]
10. A new ultra-low-dose combination oral contraceptive.
Woutersz TB
J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
[TBL] [Abstract][Full Text] [Related]
11. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
12. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
13. Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion.
Schleussner E; Brueckner T; Brautigam J; Michels W
Gynecol Endocrinol; 2001 Aug; 15(4):259-64. PubMed ID: 11560098
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone.
Shoupe D
Obstet Gynecol; 1994 May; 83(5 Pt 1):679-85. PubMed ID: 8164925
[TBL] [Abstract][Full Text] [Related]
16. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO; op ten Berg MT; Coelingh Bennink HJ
Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
[TBL] [Abstract][Full Text] [Related]
17. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
van der Does J; Exalto N; Dieben T; Bennink HC
Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
[TBL] [Abstract][Full Text] [Related]
18. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group.
Bruni V; Croxatto H; De La Cruz J; Dhont M; Durlot F; Fernandes MT; Andrade RP; Weisberg E; Rhoa M
Gynecol Endocrinol; 2000 Apr; 14(2):90-8. PubMed ID: 10836195
[TBL] [Abstract][Full Text] [Related]
19. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation.
Serup J; Bostofte E; Larsen S; Westergaard J
Acta Obstet Gynecol Scand; 1981; 60(2):203-6. PubMed ID: 7018165
[TBL] [Abstract][Full Text] [Related]
20. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
Csemiczky G; Dieben T; Coeling Bennink HJ; Landgren BM
Contraception; 1996 Dec; 54(6):333-8. PubMed ID: 8968661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
